EMD Millipore Provides Grant to The Breast Cancer Research Foundation

  EMD Millipore Provides Grant to The Breast Cancer Research Foundation

  *4-year, $500,000 grant will support two breast cancer research projects
    led by stellar scientists
  *The first project focuses on molecular screening
  *EMD Millipore is committed to investing in innovative research to further
    understanding of breast cancer

Business Wire

BILLERICA, Mass. -- October 01, 2012

EMD Millipore, the Life Science division of Merck KGaA of Germany, today
announced the company is providing The Breast Cancer Research Foundation
(BCRF) with a four-year, $500,000 grant to support leading scientists focused
on promising areas of breast cancer research. The fund will be in the form of
two grants of $250,000 each over a two-year period, and is the latest
development in EMD Millipore’s two-year alliance with BCRF.

“EMD Millipore is proud of our successful collaboration with The Breast Cancer
Research Foundation, and the opportunity to enhance our involvement to further
important breast cancer research,” said Robert Yates, President, EMD
Millipore. “We look forward to learning more about the findings from the
research conducted by the grant recipients, which may have the potential to
provide new treatment options for people living with breast cancer, or
ultimately, a world free of breast cancer.”

“Organizations like EMD Millipore, through its commitment to advancing cancer
research and its generosity, enable us to move closer to our goal of
prevention and a cure for breast cancer,” said Margaret Mastrianni, BCRF
Deputy Director. “We are delighted to be working with EMD Millipore again this
year. Its philanthropy sets a stellar example for other companies.”

One of the grant recipients is Dr. Martine Piccart-Gebhart who is a Professor
of Oncology at the Universite Libre de Bruxelles and Director of Medicine at
the Jules Bordet Institute, in Brussels, Belgium. Dr. Piccart is co-founder
and chair of the Breast International Group (BIG), uniting 50 academic
research groups from around the world and running over 30 trials under its
umbrella. BIG’s research programs include NeoBIG, an innovative biomarker and
drug development program focused on neo-adjuvant trials. Dr. Piccart’s current
BCRF-funded research, made possible by support from EMD Millipore, will focus
on molecular screening of individual tumors, which will ultimately make it
possible to tailor treatment decisions for each individual living with breast
cancer. In the coming year, the molecular screening study called INTEGRATE,
which to date has focused on neoadjuvant treatment (for primary breast
cancers, prior to surgery) will be expanded to include metastatic patients.

In 2010, EMD Millipore provided a $25,000 grant to fund the BCRF’s research
efforts. In addition, the company donated a portion of proceeds from the sale
of Guava® Flow Cytometry EasyCyte™ systems to BCRF. Flow cytometry is a
technique used by scientists to measure physical and/or chemical changes
within individual cells. These changes may occur as a consequence of many
important factors, including cancer development.

EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers
a broad range of innovative, performance products, services and business
relationships that enable our customers' success in research, development and
production of biotech and pharmaceutical drug therapies. Through dedicated
collaboration on new scientific and engineering insights, and as one of the
top three R&D investors in the Life Science Tools industry, EMD Millipore
serves as a strategic partner to customers and helps advance the promise of
life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000
employees, operations in 67 countries and 2011 revenues of EUR 2.4 billion.
EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

About Merck

All Merck Press Releases are distributed by e-mail at the same time they
become available on the Merck Website. Please go to
http://www.merck.de/subscribe to register online, change your selection or
discontinue this service.

Merck is a global pharmaceutical and chemical company with total revenues of €
10.3 billion in 2011, a history that began in 1668, and a future shaped by
more than 40,000 employees in 67 countries. Its success is characterized by
innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and shareholders own the remaining approximately
30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an
independent company ever since.

About BCRF

The Breast Cancer Research Foundation®, founded by Evelyn H. Lauder in 1993,
is an independent not-for-profit organization committed to funding scientific
research to achieve prevention and a cure for breast cancer in our lifetime.
In October 2012, BCRF will award $40 million to 197 scientists across the
United States, Canada, Latin America, Europe, the Middle East, Australia, and
China. With 91 cents of every dollar spent by BCRF directed towards breast
cancer research and awareness programs, BCRF remains one of the most fiscally
responsible charities in the country. For the tenth time since 2002, it has
earned 4 stars from Charity Navigator. Additionally, BCRF is the only cancer
organization rated an “A+” by CharityWatch. For more information about BCRF,
visit www.bcrfcure.org.

Contact:

For EMD Millipore
Jennifer Bianco, 978-715-1594
jennifer.bianco@merckgroup.com
 
Press spacebar to pause and continue. Press esc to stop.